Loading organizations...
Cellscript develops advanced messenger RNA (mRNA) technologies, offering proprietary synthesis kits and modified nucleoside transcription systems. These tools enable efficient, robust RNA translation in cells, facilitating high-quality mRNA for biological research, clinical studies, and therapeutic applications.
Established in 2007 as part of EPICENTRE Biotechnologies, Cellscript gained independence in 2011 following Illumina's acquisition. This move allowed a dedicated focus on mRNA solutions. Gary Dahl, a key figure from EPICENTRE, leads as CEO, bringing extensive biotechnology experience. The founding insight centered on the demand for specialized, high-performance mRNA synthesis.
Cellscript’s products support researchers in clinical research, drug discovery, and novel therapeutic development. The company’s mission is to continuously advance mRNA technology, providing effective tools for leveraging RNA for cellular translation. It aims to empower breakthroughs in the burgeoning field of RNA-based medicine.
Cellscript has 1 tracked investment across 1 company. The latest tracked deal is $5.0M Series B in Alethia BioTherapeutics in November 2012.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 1, 2012 | Alethia BioTherapeutics | $5.0M Series B | — | BDC Venture Capital, Agechem, GO Capital |
